Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing

Contributed Opinion
  ()
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer. read more >

Biotech's Target Price Increased as Shares 'Deeply Undervalued'

Research Report
  ()
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer. read more >

Analyst Says Biotech Share Price Could Potentially 'Double'

Research Report
  ()
Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. read more >

Biotech with Solid Pipeline and 'Solid Partnership Outlook'

Research Report
  ()
Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans. read more >

Target Price Raised on 'Undervalued' Antibiotics Developer

Research Report
  ()
Analyst Ed Arce discussed the rationale behind H.C. Wainwright & Co.'s decision to revise its models on this clinical-stage biopharmaceutical company. read more >

Biotech Reports Positive Topline Data; Biologics License Application in Progress

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., reviewed the recent clinical trial results released by this developer of cell therapies targeting oncology and orphan indications. read more >

Could a FDA Warning Letter Provide a Silver Lining to This Home Care Medical Device Company?

Contributed Opinion
  ()
Maj Soueidan, cofounder of GeoInvesting, profiles his long history with a company providing medical devices for the home care market. read more >
Expert Investing Ideas

"We believe 2018 could prove to be a pivotal year for DRRX."

–Francois Brisebois, Laidlaw & Company


"We continue to be positive about DRRX's story."

–Grant Zeng, Zacks Small-Cap Research


"DRRX is now highly attractive as a potential speculative play."

–Terry Chrisomalis, Biotech Analysis Central


"VIVE's Q3/17 revenue of ~$4.1M compares to our $3.7M estimate."

–Brian Marckx, Zacks Small-Cap Research


"DRRX will initiate three Phase 2 trials in the near term."

–Francois Brisebois, Laidlaw & Company


The Silver and Gold Summit

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Big Biotech's Value Is Bolstered by Focus on Alzheimer's Disease

Research Report
  ()
An analysis of this company's quarterly update highlights a pipeline studded with candidates targeting neurological indications. read more >

Drug Offers 'Best-in-Class' Potential

Contributed Opinion
  ()
John McCamant, editor of the Medical Technology Stock Letter, initiated coverage on a company that he calls an emerging leader in women's health. read more >

Coverage Initiated on Gene Therapy Company

Research Report
  ()
Analyst David Nierengarten with Wedbush explained the rationale for adding this biotech to his coverage universe. read more >

Analyst Calls Biotech with Alzheimer's Therapy a 'High Risk, High Reward Opportunity'

Research Report
  ()
Mackie Research reported on this company's recent announcement about one of its product candidates targeting Alzheimer's disease. read more >
The Silver and Gold Summit